Publications by authors named "Mari Aso"

Claim this Profile
R
Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression in elderly patients: a subgroup analysis of HOT/NJLCG2001.
Kazunari Tateishi, Hidenori Mizugaki, Yasuyuki Ikezawa, Ryo Morita, Keiki Yokoo, Mari Aso

Jpn J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis.
Yasuyuki Ikezawa, Ryo Morita, Hidenori Mizugaki, Kazunari Tateishi, Keiki Yokoo, Mari Aso

Cancer Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).
Kosuke Tsuji, Hidenori Mizugaki, Keiki Yokoo, Maki Kobayashi, Yosuke Kawashima, Mari Aso

Cancer Sci· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab Therapy in Lung Cancer Associated with IgG4-related Disease.
Mari Aso, Hiroki Suzuki, Takafumi Aizawa, Sachie Nawa, Hiroki Ota

Intern Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transbronchial cryobiopsy using an ultrathin cryoprobe with a guide sheath for the diagnosis of pulmonary mucosa-associated lymphoid tissue lymphoma.
Hitomi Nogawa, Hiroki Suzuki, Hiroki Ota, Yuta Kanno, Sosuke Kume, Mari Aso

J Thorac Dis· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pituitary hypoadrenocorticism and hypothyroidism after immunochemotherapy followed by salvage surgery for lung cancer: a case report.
Chikara Nakagami, Makoto Endoh, Marina Nakatsuka, Kenta Nakahashi, Hiroki Ota, Mari Aso

Gen Thorac Cardiovasc Surg Cases· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression.
Yasuyuki Ikezawa, Hidenori Mizugaki, Ryo Morita, Kazunari Tateishi, Keiki Yokoo, Mari Aso

Cancer Sci· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab-associated Dermatomyositis in Advanced Small-cell Lung Carcinoma.
Yoshitaka Yamaguchi, Mari Aso, Hikaru Nagasawa, Manabu Wada

Intern Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.
Kana Ono, Hirotaka Ono, Yukihiro Toi, Jun Sugisaka, Mari Aso

Cancer Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study.
Yukihiro Toi, Yuichiro Kimura, Yutaka Domeki, Sachiko Kawana, Tomoiki Aiba, Mari Aso

Sarcoidosis Vasc Diffuse Lung Dis· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.
Mari Aso, Yukihiro Toi, Jun Sugisaka, Tomoiki Aiba, Sachiko Kawana

Oncologist· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab.
Jun Sugisaka, Yukihiro Toi, Masataka Taguri, Yosuke Kawashima, Tomoiki Aiba, Mari Aso

JMA J· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Yukihiro Toi, Shunichi Sugawara, Jun Sugisaka, Hirotaka Ono, Yosuke Kawashima, Mari Aso

JAMA Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis